To understand whether the mechanisms associated with delayed onset of resistance in the BRAF PTEN model of melanoma aligned to those identified in vitro, we analyzed the expression patterns of key biomarkers in BRAF PTEN melanomas in vivo. Here, BRAF is linked to melanoma.